{"name":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","slug":"shanghai-chia-tai-tianqing-pharmaceutical-technology-develop","ticker":"","exchange":"","domain":"shanghaichiataitianqingtechnologydevelopment.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Placebo of TQH2722 injection","genericName":"Placebo of TQH2722 injection","slug":"placebo-of-tqh2722-injection","indication":"Other","status":"phase_3"},{"name":"TQH2722 injection","genericName":"TQH2722 injection","slug":"tqh2722-injection","indication":"Other","status":"phase_3"},{"name":"Placebo of TQC2731","genericName":"Placebo of TQC2731","slug":"placebo-of-tqc2731","indication":"Other","status":"phase_3"},{"name":"TQB2934 injection","genericName":"TQB2934 injection","slug":"tqb2934-injection","indication":"Other","status":"phase_1"},{"name":"TQC2731 injection","genericName":"TQC2731 injection","slug":"tqc2731-injection","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TQB2825 Injection","genericName":"TQB2825 Injection","slug":"tqb2825-injection","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Placebo of TQH2722 injection","genericName":"Placebo of TQH2722 injection","slug":"placebo-of-tqh2722-injection","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"TQH2722 injection","genericName":"TQH2722 injection","slug":"tqh2722-injection","phase":"phase_3","mechanism":"TQH2722 injection's mechanism is not publicly available.","indications":[],"catalyst":""},{"name":"Placebo of TQC2731","genericName":"Placebo of TQC2731","slug":"placebo-of-tqc2731","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"TQB2825 Injection","genericName":"TQB2825 Injection","slug":"tqb2825-injection","phase":"phase_3","mechanism":"TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"TQB2934 injection","genericName":"TQB2934 injection","slug":"tqb2934-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQC2731 injection","genericName":"TQC2731 injection","slug":"tqc2731-injection","phase":"phase_3","mechanism":"TQC2731 injection's mechanism is not publicly available.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}